Langbahn Team – Weltmeisterschaft

Ioxilan

Ioxilan
Clinical data
Trade namesOxilan
AHFS/Drugs.comFDA Professional Drug Information
Routes of
administration		intravenously
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityN/A
Protein bindingnegligible
Metabolismnone
Elimination half-life2 hours
ExcretionMostly renal
Identifiers
  • 1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H24I3N3O8
Molar mass791.116 g·mol−1
3D model (JSmol)
  • O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
  • InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) checkY
  • Key:UUMLTINZBQPNGF-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ioxilan is a diagnostic contrast agent.[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017.[2]

Mechanism of action

Ioxilan is an iodinated contrast agent.[2]

References

  1. ^ Cheng KT (December 2007). "Ioxilan carbonate particles". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641969.
  2. ^ a b Oxilan FDA Professional Drug Information. Accessed 2021-04-07.
Quelle: http://en.wikipedia.org/wiki/Ioxilan